Spike glycoprotein, S glycoprotein receptor binding domain, S-RBD, EY6A

SARS-CoV-2

CPC513A pdf (datasheet)

50 µg

Please Inquire

1.0 mg/ml

New catalog number RVV00306

Recombinant Human anti-SARS-CoV-2 Spike Protein Receptor Binding Domain, Clone EY6A, is expressed in XtenCHO. EY6A was identified from a convalescent patient was found to recognize the RBD and shown to be highly neutralizing. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Surface glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

Spike glycoprotein

P0DTC2

Recognizes SARS-CoV-2 Spike-RBD protein

Human

Originally isolated from a recovered SARS-CoV-2 patient

IgG

EY6A

Sterile-filtered PBS, pH 7.5 preservative free.

Protein A affinity chromatography

ELISA, FS , Neutralizing , WB

ELISA: suggested dilution 1:5,000 - 1:10,000
Western blot: suggested dilution 1:1,000 - 1:2,000

Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare working aliquots of undiluted product and store -20°C to -80°C.